Drug Trial Radar · NCT06303505
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
334
Planned (sponsor's estimate)
Start
Jun 12, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer or non-small cell lung cancer (NSCLC). The primary objectives of this study are: Phase 1: To determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) or the identified dose for optimization (IDO). Phase 2a: To assess safety of TUB-040, the preliminary efficacy of TUB-040, and to identify the recommended phase II dose (RP2D) for further development of TUB-040 . Phase 2b: To determine the efficacy of TUB-040 in patients with PROC.
Conditions
- Ovarian Cancer
- Non-small Cell Lung Cancer
Interventions
TUB-040Drug
Administered intravenous (IV) on day 1 of each 21-day treatment cycle
BevacizumabDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs)Time frame: First dose up to 21 days
- Phase 1 and 2a: Percentage of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs)Time frame: First dose date up to 30 days post last dose (Up to 3 years)
- Phase 2a & 2b: Overall Response Rate (ORR) by Blinded Independent Central Review (BICR)Time frame: Up to 3 years
Locations
21 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Winship Cancer Institute Emory University
Atlanta, Georgia · Recruiting
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts · Recruiting
START New Jersey (Astera Cancer Center)
East Brunswick, New Jersey · Recruiting
Mount Sinai
New York, New York · Recruiting
The Christ Hospital Physicians - Mt. Auburn
Cincinnati, Ohio · Recruiting
Ohio State University CRS
Columbus, Ohio · Recruiting
Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Asante Rogue Region al Medical Center
Medford, Oregon · Recruiting
START Dallas Fort Worth
Fort Worth, Texas · Recruiting
NEXT Oncology Dallas
Irving, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
UZ Leuven - PPDS
Leuven, Belgium · Recruiting
Charité- Universitaetsmedizin Berlin
Berlin, Germany · Recruiting
University Hospital of Cologne
Cologne, Germany · Recruiting
ARENSIA Exploratory Medicine, LLC
Cluj-Napoca, Romania · Recruiting
Clínica Universidad de Navarra - Madrid
Madrid, Spain · Recruiting
NEXT Madrid, University Hospital Quironsalud Madrid
Madrid, Spain · Recruiting
ARENSIA Exploratory Medicine, LLC
Kyiv, Ukraine · Active not recruiting
Guy's Hospital
London, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.